| Item Type | Name |
|
Academic Article
|
Allogenic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9.
|
|
Academic Article
|
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia.
|
|
Academic Article
|
CD5-negative chronic lymphocytic leukemia or monoclonal B-lymphocytosis of undetermined significance?
|
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
|
Academic Article
|
Diphtheria toxin conjugate therapy of cancer.
|
|
Academic Article
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
|
|
Academic Article
|
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature.
|
|
Academic Article
|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
|
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
|
Academic Article
|
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
|
Academic Article
|
Hyperleukocytosis from arsenic trioxide.
|
|
Academic Article
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
|
Academic Article
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
|
|
Academic Article
|
Auto-SCT for AML in second remission: CALGB study 9620.
|
|
Academic Article
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
|
|
Academic Article
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia.
|
|
Academic Article
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
|
|
Academic Article
|
Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
|
|
Academic Article
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
|
Academic Article
|
The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.
|
|
Academic Article
|
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.
|
|
Academic Article
|
A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
|
Academic Article
|
A longitudinal investigation of posttraumatic growth in adult patients undergoing treatment for acute leukemia.
|
|
Academic Article
|
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
|
|
Academic Article
|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
|
|
Academic Article
|
Acute promyelocytic leukemia: progress far and wide.
|
|
Academic Article
|
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
|
|
Academic Article
|
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
|
|
Academic Article
|
Anthrax fusion protein therapy of cancer.
|
|
Academic Article
|
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
|
|
Academic Article
|
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.
|
|
Academic Article
|
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
|
|
Academic Article
|
Constitutional pericentric inversion of chromosome 9 and acute leukemia.
|
|
Academic Article
|
Acute myelocytic leukemia with rare t(2;11)(q31;p13), skin rash, and fever of unknown origin.
|
|
Academic Article
|
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
|
Academic Article
|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
|
|
Academic Article
|
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
|
|
Academic Article
|
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
|
|
Academic Article
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Academic Article
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Academic Article
|
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
|
|
Academic Article
|
What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
|
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
|
Academic Article
|
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
|
|
Academic Article
|
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
|
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
|
Academic Article
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
|
Concept
|
Survival Rate
|
|
Concept
|
Disseminated Intravascular Coagulation
|
|
Concept
|
Drug Screening Assays, Antitumor
|
|
Concept
|
Chromosomes, Human, Pair 15
|
|
Concept
|
Receptors, CXCR
|
|
Concept
|
Central Nervous System Neoplasms
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Burkitt Lymphoma
|
|
Concept
|
Receptors, CXCR4
|
|
Concept
|
Body Surface Area
|
|
Concept
|
Ergocalciferols
|
|
Concept
|
Caprylates
|
|
Concept
|
Etoposide
|
|
Concept
|
Chromosomes, Human, Pair 11
|
|
Concept
|
Expressed Sequence Tags
|
|
Concept
|
Plant Extracts
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Cell Cycle
|
|
Concept
|
Core Binding Factor Alpha 2 Subunit
|
|
Concept
|
Epigenesis, Genetic
|
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
|
Concept
|
HL-60 Cells
|
|
Concept
|
Clone Cells
|
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Antigens, CD34
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Ideal Body Weight
|
|
Concept
|
Chromosomes, Human, Pair 3
|
|
Concept
|
Administration, Oral
|
|
Concept
|
Blood Cell Count
|
|
Concept
|
Dogs
|
|
Concept
|
Chromosomal Proteins, Non-Histone
|
|
Concept
|
Trans-Activators
|
|
Concept
|
Amino Acid Sequence
|
|
Concept
|
Chromosomes, Human
|
|
Concept
|
Intensive Care Units
|
|
Concept
|
Geriatric Assessment
|
|
Concept
|
Hydroxamic Acids
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Ubiquitin Thiolesterase
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Cell Respiration
|
|
Concept
|
Acute Disease
|
|
Concept
|
Colorectal Neoplasms
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Antigens, Differentiation, Myelomonocytic
|
|
Concept
|
Injections, Subcutaneous
|
|
Concept
|
Tumor Stem Cell Assay
|
|
Concept
|
Translocation, Genetic
|
|
Concept
|
Diabetes Mellitus
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Genetic Loci
|
|
Concept
|
Pathology, Molecular
|
|
Concept
|
Tumor Cells, Cultured
|
|
Concept
|
Biopsy
|
|
Concept
|
Filgrastim
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Infusions, Intravenous
|
|
Concept
|
Erythrocyte Transfusion
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Chromosome Inversion
|
|
Concept
|
Chromosomes, Human, Pair 7
|
|
Concept
|
Cell Differentiation
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Nursing Assessment
|
|
Concept
|
Diarrhea
|
|
Concept
|
Immunotoxins
|
|
Concept
|
Repressor Proteins
|
|
Concept
|
Cytogenetic Analysis
|
|
Concept
|
Angiogenic Proteins
|
|
Concept
|
Exons
|
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
|
Concept
|
Diabetes Mellitus, Type 2
|
|
Concept
|
Genes, ras
|
|
Concept
|
Codon
|
|
Concept
|
Chromosomes, Human, Pair 9
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Boronic Acids
|
|
Concept
|
Platelet Count
|
|
Concept
|
Bacillus anthracis
|
|
Concept
|
Genes, Neoplasm
|
|
Concept
|
Academic Medical Centers
|
|
Concept
|
Loss of Heterozygosity
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Antigens, CD
|
|
Concept
|
Chromosomes, Human, Pair 22
|
|
Concept
|
Genes, p53
|
|
Concept
|
Drug Synergism
|
|
Concept
|
fms-Like Tyrosine Kinase 3
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Severity of Illness Index
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Thalidomide
|
|
Concept
|
Cytokines
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Vascular Malformations
|
|
Concept
|
Age Factors
|
|
Concept
|
Karyotyping
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Central Nervous System Diseases
|
|
Concept
|
Apoptosis
|
|
Concept
|
Receptors, Urokinase Plasminogen Activator
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Cyclin D1
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Community Networks
|
|
Concept
|
Mitochondria
|
|
Concept
|
Culture
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Incidence
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Chromosomes, Human, Pair 17
|
|
Concept
|
Recurrence
|
|
Concept
|
Cell Division
|
|
Concept
|
Trisomy
|
|
Concept
|
Asparaginase
|
|
Concept
|
Disease Progression
|
|
Concept
|
Tandem Repeat Sequences
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Monosomy
|
|
Concept
|
Aorta, Thoracic
|
|
Concept
|
Diphtheria Toxin
|
|
Concept
|
Cytarabine
|
|
Concept
|
Leukemia, Myeloid, Accelerated Phase
|
|
Concept
|
Tretinoin
|
|
Concept
|
Endothelial Growth Factors
|
|
Concept
|
Chromosomes, Human, Pair 5
|
|
Concept
|
Genes, Wilms Tumor
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
CCAAT-Enhancer-Binding Proteins
|
|
Concept
|
Chromosomes, Human, Pair 21
|
|
Concept
|
Chromosomes, Human, Pair 8
|
|
Concept
|
Blast Crisis
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Subclavian Artery
|
|
Concept
|
Cytogenetics
|
|
Concept
|
Urokinase-Type Plasminogen Activator
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
Benzamides
|
|
Concept
|
Thymidine
|
|
Concept
|
Aziridines
|
|
Concept
|
Cell Line
|
|
Concept
|
Chromosome Deletion
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
Uniparental Disomy
|
|
Concept
|
Sulfides
|
|
Concept
|
Cardiovascular Abnormalities
|
|
Concept
|
Antigens, Differentiation, B-Lymphocyte
|
|
Concept
|
In Situ Hybridization, Fluorescence
|
|
Concept
|
U937 Cells
|
|
Concept
|
Risk Factors
|
|
Concept
|
Daunorubicin
|
|
Concept
|
Azacitidine
|
|
Concept
|
Genes, erbB-1
|
|
Concept
|
Alleles
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Oxides
|
|
Concept
|
Comorbidity
|
|
Concept
|
Cell Line, Tumor
|
|
Concept
|
Chromosomes, Human, Pair 2
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Antibiotics, Antineoplastic
|
|
Concept
|
Cyclin D2
|
|
Academic Article
|
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.
|
|
Academic Article
|
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
|
|
Academic Article
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
|
Academic Article
|
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
|
|
Academic Article
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
|
Academic Article
|
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
|
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
|
Academic Article
|
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
|
|
Academic Article
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
|
Academic Article
|
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).
|
|
Academic Article
|
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
|
|
Academic Article
|
Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
|
|
Academic Article
|
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
|
|
Academic Article
|
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
|
|
Academic Article
|
Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donor.
|
|
Academic Article
|
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
|
|
Academic Article
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
|
|
Academic Article
|
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.
|
|
Academic Article
|
Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).
|
|
Academic Article
|
Exercise for older adult inpatients with acute myelogenous leukemia: A pilot study.
|
|
Academic Article
|
Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.
|
|
Academic Article
|
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
|
|
Academic Article
|
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
|
|
Academic Article
|
Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
|
|
Academic Article
|
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.
|
|
Academic Article
|
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
|
|
Academic Article
|
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.
|
|
Academic Article
|
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
|
|
Academic Article
|
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
|
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
|
Academic Article
|
Vascular ring presenting as dysphagia in an adult woman: a case report.
|
|
Academic Article
|
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
|
|
Academic Article
|
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
No evidence for microsatellite instability in acute myeloid leukemia.
|
|
Academic Article
|
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
|
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
|
Academic Article
|
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.
|
|
Academic Article
|
Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
|
|
Academic Article
|
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
|
|
Academic Article
|
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.
|
|
Academic Article
|
Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.
|
|
Academic Article
|
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
|
|
Academic Article
|
A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
|
|
Academic Article
|
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
|
|
Academic Article
|
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.
|
|
Academic Article
|
Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.
|
|
Academic Article
|
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
|
|
Academic Article
|
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
|
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
|
Academic Article
|
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
|
|
Academic Article
|
Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.
|
|
Academic Article
|
Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.
|
|
Academic Article
|
Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia.
|
|
Academic Article
|
Goals and Adverse Effects: Rate of Concordance Between Patients and Providers.
|
|
Academic Article
|
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
|